Nilotinib Torrent (Nilotinib)

Nilotinib is a targeted therapy that inhibits BCR‑ABL driven leukemic pathways. It is indicated for the following conditions:

• Chronic myeloid leukemia (CML): improves disease control and prolongs survival across chronic, accelerated and blast phases.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when used in combination regimens.
• Accelerated‑phase CML: helps achieve cytogenetic and molecular responses in patients progressing beyond chronic phase.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase as well as PDGFR and c‑KIT receptors. By binding to the ATP‑binding site of these kinases, it blocks downstream signaling that drives uncontrolled proliferation of leukemic cells, thereby restoring normal cell cycle regulation and inducing apoptosis in Philadelphia chromosome‑positive malignancies.

Nilotinib may cause a range of adverse reactions. Patients should be monitored regularly for both common and serious events.

Common Side Effects

• Nausea
• Diarrhea
• Rash or skin discoloration
• Fatigue
• Headache
• Arthralgia

Serious or Rare Side Effects

• QT interval prolongation leading to arrhythmia
• Pancreatitis
• Severe hepatic injury
• Grade 3/4 neutropenia
• Grade 3/4 thrombocytopenia
• Stevens‑Johnson syndrome or toxic epidermal necrolysis

Nilotinib requires careful monitoring and patient education before and during therapy.

• Cardiac monitoring: baseline and periodic ECGs to detect QT prolongation.
• Hepatic function: assess liver enzymes before initiation and during treatment.
• Hematologic surveillance: regular complete blood counts to identify neutropenia or thrombocytopenia.
• Pregnancy risk: contraindicated in pregnancy (Category D); advise effective contraception.
• Elderly patients: use with caution due to increased susceptibility to cardiac and metabolic effects.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Nilotinib interacts with several drug classes; clinicians should review concomitant medications.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure and toxicity.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering plasma levels.
• Antacids or proton‑pump inhibitors that raise gastric pH: can markedly decrease nilotinib absorption.
• Other QT‑prolonging agents (e.g., fluoroquinolones, antiarrhythmics): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CYP3A4 substrates with narrow therapeutic index (e.g., warfarin, certain statins): may require dose adjustment.
• Oral contraceptives: reduced effectiveness possible, advise alternative contraception.
• Diuretics that affect electrolyte balance: monitor potassium and magnesium levels.
• Antifungal azoles with moderate CYP3A4 inhibition (e.g., fluconazole): may modestly raise nilotinib levels.